Influencing Factors for Cure of Clonorchiasis by Praziquantel Therapy: Infection Burden and CYP3A5 Gene Polymorphism
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Chemotherapy of clonorchiasis with praziquantel (PZQ) is effective but about 15% of treated cases have been reported uncured. The present study investigated correlation of single nucleotide polymorphisms (SNPs) of the cytochrome P450 gene, CYP3A5 and cure of clonorchiasis. A total of 346 egg passing residents were subjected and treated by 3 doses of 25 mg/kg PZQ. Reexamination recognized 33 (9.5%) uncured and 313 cured. Numbers of eggs per gram of feces (EPGs) before treatment were significantly lower in the cured group than in the uncured group (2,011.2±3,600.0 vs 4,998.5±7,012.0, P<0.001). DNAs of the subjects were screened for SNPs at 7 locations of CYP3A5 using PCR. In the uncured group, the SNP frequencies at g.-20555G>A and g.27526C>T of CYP3A5 were 15.2% and 9.1% while those were 3.8% and 1.0%, respectively, in the cured group. The cure rate was significantly lower in the cases with SNP at g.27526C>T and EPGs≥1,000. In conclusion, EPGs and SNPs of CYP3A5 are factors which influence cure of clonorchiasis by PZQ therapy. It is strongly suggested to recommend 2-day medication for individuals with high EPGs≥1,000.
Abstract
Chemotherapy of clonorchiasis with praziquantel (PZQ) is effective but about 15% of treated cases have been reported uncured. The present study investigated correlation of single nucleotide polymorphisms (SNPs) of the cytochrome P450 gene, CYP3A5 and cure of clonorchiasis. A total of 346 egg passing residents were subjected and treated by 3 doses of 25 mg/kg PZQ. Reexamination recognized 33 (9.5%) uncured and 313 cured. Numbers of eggs per gram of feces (EPGs) before treatment were significantly lower in the cured group than in the uncured group (2,011.2±3,600.0 vs 4,998.5±7,012.0, P<0.001). DNAs of the subjects were screened for SNPs at 7 locations of CYP3A5 using PCR. In the uncured group, the SNP frequencies at g.-20555G>A and g.27526C>T of CYP3A5 were 15.2% and 9.1% while those were 3.8% and 1.0%, respectively, in the cured group. The cure rate was significantly lower in the cases with SNP at g.27526C>T and EPGs≥1,000. In conclusion, EPGs and SNPs of CYP3A5 are factors which influence cure of clonorchiasis by PZQ therapy. It is strongly suggested to recommend 2-day medication for individuals with high EPGs≥1,000.
참고문헌 (13)
- Lun ZR, "Clonorchiasis: a key foodborne zoonosis in China", Lancet Infect Dis, 5, pp.31~41 (2005)
- 조신형, "Prevalence of Clonorchiasis in Southern Endemic Areas of Korea in 2006", The Korean Journal of Parasitology, 46(3), pp.133~137 (2008), 대한기생충학회
- Seo BS, "Praziquantel (Distocide®) in treatment of Clonorchis sinensis infection", Korean J Parasitol, 21, pp.241~245 (1983)
- Rim HJ, "The current pathobiology and chemotherapy of clonorchiasis", Korean J Parasitol, 24, pp.1~141 (1986)
- Hong ST, "Chung BS, Seo M, Choi MH. Sustained-release praziquantel tablet: pharmacokinetics and he treatment of clonorchiasis in beagle dogs", Parasitol Res, 91, pp.316~320 (2003)
- Cioli D, "Praziquantel", Parasitol Res, 90(1), pp.3~9 (2003)
- Lee SJ, "Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups", Pharmacogenetics, 13, pp.461~472 (2003)
- Roy JN, "CYP3A5 genetic polymorphisms in different ethnic populations", Drug Metab Dispos, 33, pp.884~887 (2005)
- Choi MH, "Effect of control strategies on prevalence, incidence and re-infection of clonorchiasis in endemic areas of China", PLoS Negl Trop Dis, 4, pp.601~ (2010)
- 최동일, "Changes in Sonographic Findings after Treatment of Patients with Clonorchiasis in a Heavy Endemic Area", The Korean Journal of Parasitology, 47(1), pp.19~23 (2009), 대한기생충학회
- Hong ST, "The Kato-Katz method is reliable for diagnosis of Clonorchis sinensis infection", Diagn Microbiol Infect Dis, 47, pp.345~347 (2003)
- Chou FC, "Genetic polymorphism of cytochrome P450 3A5 in Chinese", Drug Metab Dispos, 29, pp.1205~1209 (2001)
- Hustert E, "The genetic determinants of the CYP3A5 polymorphism", Pharmacogenetics, 11, pp.773~779 (2001)